Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug ...
Over 100 NPM and PyPI packages were injected with malicious code in the Miasma and Hades Shai-Hulud supply chain attack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results